Where is Janux Therapeutics (JANX) Headed According to Analysts?
Janux Therapeutics (JANX) is highlighted as a top immunotherapy stock, with JonesTrading maintaining a Buy rating and a $50 price target. The company recently announced a collaboration with Bristol Myers Squibb to develop a novel tumor-activated therapeutic, validating Janux's platform and expanding its oncology reach. Janux will handle preclinical development, while Bristol Myers Squibb will manage subsequent development and commercialization globally.
Janux therapeutics doses first participant in JANX011 phase 1 trial
Janux Therapeutics has dosed the first participant in a Phase 1 clinical study for JANX011, a CD19-targeted bispecific therapy for autoimmune diseases. This marks the first clinical evaluation of their Adaptive Immune Response Modulator (ARM) platform, aiming to deplete CD19-expressing B cells without lymphodepletion. The company is also collaborating with Bristol Myers Squibb and recently appointed a new Chief Medical Officer, though its stock was downgraded by Clear Street due to concerns about its cancer treatment platform.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics reported that the first patient has been dosed in a Phase 1 clinical study for JANX011, a CD19-targeted bispecific engineered using its Adaptive Immune Response Modulator (ARM) platform. JANX011 is designed for autoimmune diseases to achieve deep and durable immune reset via targeted depletion of CD19-expressing B cells. This milestone marks the first clinical evaluation of Janux's ARM platform, which aims to provide sustained B-cell depletion with improved safety compared to conventional T-cell engagers.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has announced that the first patient has been dosed in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific engineered using its proprietary Adaptive Immune Response Modulator (ARM) platform. JANX011 is being developed for autoimmune diseases and aims to achieve deep and durable immune reset through targeted depletion of CD19-expressing B cells. This milestone represents the first clinical evaluation of Janux's ARM platform, which is designed to enable sustained target B-cell depletion with improved safety and convenience compared to conventional T-cell engagers.
Janux therapeutics doses first participant in JANX011 phase 1 trial
Janux Therapeutics has dosed the first participant in its Phase 1 clinical study for JANX011, a CD19-targeted bispecific therapy for autoimmune diseases, marking a key milestone for its ARM platform. The therapy aims to deplete B cells and reset the immune system, with preclinical studies showing promising results without requiring harsh pre-conditioning. This development follows recent news of a collaboration with Bristol Myers Squibb and a downgrade from Clear Street due to concerns about Janux's cancer treatment platform.
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX011
Janux Therapeutics has dosed the first patient in a Phase 1 clinical study of JANX011, a CD19-targeted bispecific developed for autoimmune diseases using its Adaptive Immune Response Modulator (ARM) platform. JANX011 aims for deep and durable immune reset through targeted B-cell depletion and is the first clinical candidate from the ARM platform. Preclinical studies showed promising results with strong B-cell depletion and low cytokine levels, suggesting a broad safety window and potential for CAR-T like effects in autoimmune patients.
Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011
Janux Therapeutics has announced that the first patient has been dosed in its Phase 1 study of Janx011. This development marks a significant step forward for the company's clinical trials. The news was reported by Refinitiv via TradingView.
Trading the Move, Not the Narrative: (JANX) Edition
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX), highlighting strong near-term sentiment despite persistent mid and long-term weakness. It identifies a mid-channel oscillation pattern and an exceptional 122.5:1 risk-reward setup targeting a 40.0% gain. The piece also details three AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Wall Street Analysts See a 319.23% Upside in Janux Therapeutics (JANX): Can the Stock Really Move This High?
Janux Therapeutics (JANX) has seen its stock gain 1.8% in the past four weeks, with Wall Street analysts projecting a potential upside of 319.2% based on a mean price target of $58.65. This optimism is further supported by strong agreement among analysts on the company's earnings prospects, evidenced by upward revisions in EPS estimates, and a Zacks Rank #2 (Buy) rating. Despite the typical skepticism advised for price targets, the trend in earnings estimate revisions suggests a legitimate reason for potential stock upside.
Janux Therapeutics, Inc. (JANX) Faces Platform Risk Amid Lack of Durability Data on JANX007
Janux Therapeutics (JANX) is facing platform risk due to a lack of durability data for its drug candidate JANX007 and the absence of new data for JANX008, leading to a downgrade by Clear Street. Despite these concerns, Janux recently entered an exclusive worldwide license and collaboration agreement with Bristol Myers (BMY) for a novel tumor-activated therapy, with potential milestones totaling over $800 million. The company is developing immunotherapies to treat cancer but is currently recommended with caution given rising competitive pressures and execution risks.
Janux Therapeutics, Inc. (JANX) faces platform risk amid lack of durability data on JANX007
This article focuses on Janux Therapeutics (JANX) and the potential platform risk associated with its drug candidate JANX007, particularly due to a lack of durability data. The primary concern is whether the drug's effects last long enough, which could impact its overall efficacy and market potential. Further clinical data will be crucial in addressing these concerns for investors and the medical community.
Janux Therapeutics, Inc. (NASDAQ:JANX) Given Consensus Rating of "Moderate Buy" by Brokerages
Janux Therapeutics (NASDAQ: JANX) has received a consensus "Moderate Buy" rating from fifteen brokerages, with an average 12-month target price of $60.08. Despite this, company insiders, including CEO David Campbell, have recently sold 25,699 shares valued at approximately $471K. The company's stock currently trades around $13.71, with a market capitalization of about $825 million, and recently reported an EPS of ($0.39) and revenue of $10.0 million, both exceeding estimates.
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator
Several insiders at Janux Therapeutics, including President David Campbell, have sold shares over the past year, with no insider purchases recorded. The largest sale involved US$111k worth of shares at US$13.73, slightly below the current price. While insiders still own 6.6% of the company, this consistent selling activity may be a red flag for shareholders.
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Bristol Myers Squibb (BMY) is strategically expanding its oncology pipeline through collaborations with Janux Therapeutics, Microsoft, and BioNTech to develop novel cancer therapies and improve early detection. These partnerships aim to boost BMY's portfolio as its legacy drugs face generic competition, positioning it to compete with pharmaceutical giants like Merck and Pfizer in the growing oncology market. Despite valuation at a discount to the large-cap pharma industry, BMY's stock has seen significant gains, though its 2025 EPS estimates have declined slightly.
Janux Therapeutics Repeat Insider Selling Not A Positive Indicator
Janux Therapeutics (NASDAQ:JANX) has seen multiple insider sales over the past year, raising a potential red flag for investors. The President, David Campbell, sold US$111k worth of shares, and in the last quarter alone, insiders divested US$261k of stock without any purchases. Despite insiders owning 6.6% of the company, the consistent selling without corresponding buying suggests caution is warranted.
Will BMY's Oncology Collaborations Drive Its Next Growth Phase?
Bristol Myers Squibb (BMY) is strategically collaborating with companies like Janux Therapeutics and BioNTech to expand its oncology pipeline and portfolio, especially as its legacy products face generic competition. These partnerships involve developing novel treatments like tumor-activated therapeutics and bispecific antibodies, with promising early clinical results in various cancer types. BMY contends with strong competition from Merck and Pfizer in the oncology market, but its shares have outperformed the industry in the last six months and are trading at a discount in terms of valuation.
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy
Janux Therapeutics has announced a partnership with Bristol-Myers Squibb to develop a new cancer treatment targeting solid tumors. Janux will handle preclinical testing before Bristol-Myers takes over clinical trials and global commercialization. The collaboration was well-received by the market, with Janux shares increasing over 12% in premarket trading.
Janux Therapeutics Partners With Bristol-Myers (BMY) on Solid Tumor Therapy
Janux Therapeutics has partnered with Bristol-Myers Squibb to develop a new cancer treatment targeting solid tumors. The collaboration, announced on January 22, 2026, involves Janux handling preclinical testing before Bristol Myers takes over for clinical trials and commercialization. Janux Therapeutics shares surged over 12% in premarket trading following the announcement.
Janux Therapeutics Taps Dr. William Go as Chief Medical Officer
Janux Therapeutics, a clinical-stage biopharmaceutical company, has appointed Dr. William Go as its new Chief Medical Officer. Dr. Go brings over 20 years of experience in hematology and oncology, having led successful programs through clinical development, regulatory approvals, and product launches at companies like A2 Biotherapeutics, Kite Pharma, and Amgen. His appointment comes as Janux advances its pipeline of novel immunotherapies, particularly its tumor-activated T-cell engager platform.
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Janux Therapeutics has appointed William Go, M.D., Ph.D., as its new Chief Medical Officer, effective January 26, 2026. Dr. Go brings over 20 years of experience in hematology and oncology, with a strong background in clinical development, regulatory approvals, and product launches. He will be instrumental in advancing Janux's pipeline, which includes candidates like JANX007 and JANX008 for various cancers, and other programs utilizing its proprietary TRACTr, TRACIr, and ARM platforms.
Janux Therapeutics Appoints William Go, M.D., Ph.D., as Chief Medical Officer
Janux Therapeutics has appointed William Go, M.D., Ph.D., as its new Chief Medical Officer, effective January 26, 2026. Dr. Go brings over 20 years of experience in hematology and oncology, including leading programs through clinical development, regulatory approvals, and product launches. He will be instrumental in advancing Janux's pipeline of novel immunotherapies and scaling its clinical and regulatory operations.
Janux Therapeutics appoints William Go as new chief medical officer
Janux Therapeutics has appointed William Go, M.D., Ph.D., as its new Chief Medical Officer, replacing Zachariah McIver. Dr. Go brings over 20 years of experience in hematology and oncology, having previously held positions at A2 Biotherapeutics, Kite Pharma, and Amgen. The company, which is advancing its immunotherapy pipeline with two clinical candidates, has a market cap of $890.79 million and analysts maintain a Strong Buy consensus.
JANX Enters Global Oncology Collaboration With BMY, Stock Rises
Janux Therapeutics (JANX) announced a global oncology collaboration and exclusive license agreement with Bristol Myers Squibb (BMY), involving Janux's proprietary Tumor Activated technologies. Janux will receive up to $50 million in upfront and near-term milestone payments, with potential for an additional $800 million in development, regulatory, and commercial milestones, plus tiered royalties on product sales. This partnership validates Janux's platform, provides significant funding, and shifts later-stage development risk to BMY, leading to a 14.1% rise in Janux shares following the announcement.
Janux Therapeutics Signs Exclusive License and Collaboration Agreement With Bristol-Myers Squibb
Janux Therapeutics has entered into an exclusive license and collaboration agreement with Bristol-Myers Squibb to develop and commercialize a novel tumor-activated therapeutic. Janux will receive a $15 million upfront payment, up to $785 million in milestones, and tiered royalties on product sales, while Bristol-Myers Squibb will handle global development and commercialization after preclinical work is completed by Janux. The agreement focuses on advancing a tumor-activated T-cell engager for solid tumors.
Janux Therapeutics, Inc. Announces Collaboration and Exclusive Worldwide License Agreement with Bristol Myers Squibb to Develop A Novel Tumor-Activated Therapeutic for Solid Tumors
Janux Therapeutics, Inc. has announced an exclusive worldwide license agreement and collaboration with Bristol Myers Squibb to develop a novel tumor-activated therapeutic for solid tumors. Under the agreement, Janux will conduct preclinical development up to IND submission, after which Bristol Myers Squibb will handle further development and global commercialization. Janux stands to receive up to $50 million in upfront and near-term milestone payments, with potential additional development, regulatory, and commercial milestones totaling approximately $800 million, alongside tiered royalties on product sales.
Janux Therapeutics Secures Exclusive License Agreement with Bristol Myers Squibb, Potential Earnings Up to $800 Million
Janux Therapeutics has entered into an exclusive worldwide license agreement with Bristol Myers Squibb to develop a tumor antigen therapeutic for various cancers. The agreement includes up to $50 million in upfront and near-term milestone payments, and approximately $800 million in additional development, regulatory, and commercial milestones. Janux will handle preclinical development, with Bristol Myers Squibb taking over clinical development and commercialization, enhancing both companies' positions in the oncology market.
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics and Bristol Myers have announced a deal worth up to $850 million for the development of a cancer drug. This agreement highlights a strategic collaboration between the two companies in the field of oncology. The news was reported by Reuters.
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux Therapeutics has partnered with Bristol Myers Squibb in a deal potentially worth up to $850 million to develop a new cancer treatment for solid tumors. Janux will receive upfront and near-term milestone payments, and could earn additional payments tied to development, regulatory approvals, and sales, along with royalties. Janux's shares rose over 12% in premarket trading following the announcement.
Clear Str Downgrades Janux Therapeutics (NASDAQ:JANX) to Hold
Clear Str downgraded Janux Therapeutics (NASDAQ:JANX) from "strong-buy" to "hold" as several other analysts also cut price targets, though the consensus remains a "Moderate Buy" with a $60.08 average target. Despite beating last quarter's EPS and revenue estimates, analysts forecast a negative EPS for the current fiscal year. Insider selling, including by the CEO, adds to the negative sentiment surrounding the company.
Clear Street downgrades Janux Therapeutics stock to Hold on efficacy concerns
Clear Street downgraded Janux Therapeutics (NASDAQ:JANX) from Buy to Hold, significantly reducing its price target to $12.00 from $32.00, due to concerns about the efficacy and durability of its cancer treatment platform, JANX007. The firm believes it's highly unlikely JANX007 will meet the median radiographic progression-free survival benchmark established by PLUVICTO. This downgrade follows Janux's recent Phase 1a and 1b trial reports, which also prompted various other analysts to adjust their ratings and price targets for JANX.
Janux Therapeutics, Inc. (NASDAQ:JANX) Short Interest Update
Janux Therapeutics (NASDAQ: JANX) experienced a significant increase in short interest, rising by 24.9% to 9,239,650 shares as of December 31st, representing 21.8% of the stock sold short with a 3.5 days-to-cover ratio. Despite analysts lowering price targets, the consensus remains a "Moderate Buy" with an average target of $60.08. Insiders sold shares totaling approximately $972,000 in the last three months, though institutional ownership is high at 75.39%.
(JANX) Price Dynamics and Execution-Aware Positioning
This article analyzes Janux Therapeutics Inc. (NASDAQ: JANX) stock, highlighting a near-term strong sentiment that may challenge persistent mid and long-term weakness. It identifies support and resistance levels, calculating an exceptional 140.5:1 risk-reward setup targeting a 42.8% gain versus 0.3% risk. The piece also outlines three distinct AI-generated trading strategies—Position, Momentum Breakout, and Risk Hedging—tailored for different risk profiles.
Bank of America Securities Keeps Their Buy Rating on Janux Therapeutics Inc (JANX)
Bank of America Securities has maintained a Buy rating on Janux Therapeutics Inc (JANX) with a price target of $35.00, citing the company's Q3 revenue of $10 million and a GAAP net loss of $24.31 million. Despite a negative corporate insider sentiment with increased selling activity, the analyst consensus remains a Strong Buy with an average price target of $55.25. Analyst Alec Stranahan, who covers the Healthcare sector, holds a 4.1% average return and 52.26% success rate on recommended stocks.
BofA Adjusts Price Target on Janux Therapeutics to $35 From $49, Maintains Buy Rating
BofA has revised its price target for Janux Therapeutics (NASDAQ:JANX) down to $35 from $49, while continuing to maintain a Buy rating on the stock. This adjustment comes despite recent positive updates on the company's clinical pipeline, including the advancement of its JANX008 program. The biotechnology company, focused on cancer immunotherapies, reports ongoing development of its TRACTr and TRACIr platforms.
Janux Therapeutics CEO Campbell sells $110k in stock
Janux Therapeutics' President and CEO, David Alan Campbell, sold 8,072 shares of common stock for $110,828. This comes amidst other recent news for the company, including progress in clinical trials for its cancer immunotherapies and various updated analyst ratings with differing price targets.
Janux Therapeutics (NASDAQ:JANX) VP Maria Dobek Sells 1,462 Shares
Janux Therapeutics VP Maria Dobek sold 1,462 shares of the company's stock on January 2nd, reducing her ownership by 8.68%. The transaction totaled $20,073.26 with shares sold at an average price of $13.73. Following the sale, Dobek now owns 15,373 shares valued at approximately $211,071.29.
Maria Dobek, Janux Therapeutics VP, sells $20k in shares
Maria Dobek, VP of Accounting at Janux Therapeutics (NASDAQ:JANX), sold 1,462 shares for $20,073 on January 2, 2026, though she also acquired a larger number of shares and stock options. Despite the stock trading near its 52-week low and being down significantly, InvestingPro analysis suggests it may be undervalued, and analysts have revised earnings upwards, though profitability is not expected this year. The company is actively progressing through clinical trials for its cancer immunotherapies, with varied analyst ratings reflecting ongoing evaluations of its biopharmaceutical potential.
Andrew Hollman Meyer Sells 1,879 Shares of Janux Therapeutics (NASDAQ:JANX) Stock
Andrew Hollman Meyer sold 1,879 shares of Janux Therapeutics (NASDAQ:JANX) stock on January 2nd for over $25,000, reducing his stake by 2.21%. This transaction is part of broader insider selling activity at Janux Therapeutics, with multiple executives, including CEO David Alan Campbell, also selling shares. Despite the insider selling, analysts maintain a "Moderate Buy" consensus rating for JANX, though several firms have recently lowered their price targets.
Janux Therapeutics’ CMO McIver sells $37k in shares
Janux Therapeutics' Chief Medical Officer, Zachariah McIver, sold 2,714 shares of common stock for $37,263 to cover tax withholding obligations. Following the transaction, McIver directly owns 23,286 shares. This insider transaction comes amidst recent updates on Janux Therapeutics' clinical trials and various analyst rating adjustments for the company.
Janux Therapeutics CBO Meyer sells $25,798 in stock
Janux Therapeutics CBO Andrew Hollman Meyer sold 1,879 shares of company stock for $25,798 to cover tax obligations. The stock is trading near its 52-week low, representing a significant decline from its high, and InvestingPro data indicates it is currently undervalued and oversold. Recent company news includes positive updates on its clinical trials and varying price targets from several analysts.
Janux Therapeutics CSO sells $34k in shares
Thomas DiRaimondo, Janux Therapeutics' CSO, sold 2,505 shares for $34,393 on January 2, 2026, while also acquiring 31,400 shares for $0 and receiving 109,900 stock options. This sale comes as the company's shares trade near a 52-week low, although InvestingPro analysts view the stock as undervalued with revised upward earnings expectations. The article also touches upon recent clinical trial updates and varied analyst ratings from Truist Securities, UBS, and Cantor Fitzgerald.
Thomas Diraimondo Sells 2,505 Shares of Janux Therapeutics (NASDAQ:JANX) Stock
Thomas Diraimondo, an insider at Janux Therapeutics (NASDAQ:JANX), sold 2,505 shares of the company's stock on January 2nd, 2026, for a total of $34,393.65. This transaction reduced his ownership by 1.97% to 124,425 shares. The stock traded at $13.65, near its 12-month low, and analysts currently have a consensus "Moderate Buy" rating with a target price of $61.08 despite recent negative EPS.
Charles Winter Sells 2,401 Shares of Janux Therapeutics (NASDAQ:JANX) Stock
Charles Winter, an insider at Janux Therapeutics (NASDAQ:JANX), sold 2,401 shares of the company's stock on January 2nd, reducing his stake by 3% to 77,721 shares. The sale occurred at an average price of $13.73 per share, totaling $32,965.73. Following this transaction, Janux Therapeutics' shares traded down 1.1% to $13.65, near its 12-month low, with a market capitalization of approximately $821 million.
Insider Selling: Janux Therapeutics (NASDAQ:JANX) Insider Sells 2,714 Shares of Stock
Janux Therapeutics (NASDAQ:JANX) Director Zachariah Mciver sold 2,714 shares of the company's stock on January 2nd at an average price of $13.73, reducing his stake by 10.44%. The transaction, valued at $37,263.22, was disclosed in an SEC filing. The company's stock traded down 1.1% to $13.65 on Friday, near its 12-month low, despite beating EPS and revenue estimates in its last earnings report and generally holding a "Moderate Buy" consensus rating from analysts.
Janux Therapeutics (NASDAQ:JANX) Sets New 52-Week Low - Here's What Happened
Janux Therapeutics (NASDAQ:JANX) reached a new 52-week low of $13.62 on Wednesday, trading well below its moving averages despite beating Q3 earnings expectations. Analyst ratings are largely positive with an average "Moderate Buy" and price target of $61.08, though several firms recently cut their targets, and insiders have been selling shares.
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (NASDAQ: JANX) is seen by Wall Street as having significant potential, with a consensus "buy" rating and high price targets suggesting substantial upside. Despite Barclays trimming its price target, the company recently provided a positive update on its Phase 1 study for JANX008, an EGFR-targeted TRACTr for various solid tumors. Janux Therapeutics is a clinical-stage biopharmaceutical company focused on developing immunotherapies for cancer.
Analysts Offer Insights on Healthcare Companies: MannKind (MNKD) and Janux Therapeutics Inc (JANX)
Analysts from Truist Financial and Wells Fargo have issued bullish sentiments for MannKind (MNKD) and Janux Therapeutics Inc (JANX) in the Healthcare sector. MannKind received a Strong Buy consensus with a 54.7% upside, while Janux Therapeutics Inc also obtained a Strong Buy consensus, projecting a 303.6% upside from current levels. These endorsements highlight significant growth potential for both companies according to financial analysts.
Why Wall Street Sees Big Potential in Janux Therapeutics, Inc. (JANX)
Janux Therapeutics, Inc. (NASDAQ: JANX) is attracting significant Wall Street attention, with analysts issuing "buy" or equivalent ratings and high price targets. The company recently completed the Phase 1a dose-escalation portion of its JANX008 study for treating various solid tumors and is now initiating expansion cohorts. Despite acknowledging JANX's potential, the article suggests that some AI stocks may offer even greater returns and lower risk.
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TD Cowen analyst Marc Frahm has maintained a Buy rating for Janux Therapeutics Inc (JANX). Frahm, a 5-star analyst, covers the Healthcare sector and boasts an average return of 16.6%. The analyst consensus for Janux Therapeutics Inc is currently a Strong Buy with an average price target of $56.42.
TD Cowen Sticks to Their Buy Rating for Janux Therapeutics Inc (JANX)
TD Cowen analyst Marc Frahm maintained a Buy rating on Janux Therapeutics Inc (JANX) on December 24, 2025. According to TipRanks, Frahm is a 5-star analyst with a 16.6% average return and a 52.78% success rate. The analyst consensus on Janux Therapeutics Inc is a Strong Buy, with an average price target of $56.42.
